APPENDIX F
Vaccine Safety

The Vaccine Adverse Event Reporting System (VAERS) ............... F-1
Table of Reportable Events Following Vaccination ................. F-2
Vaccine Adverse Event Reporting System (VAERS) Form .......... F-6
The Vaccine Injury Compensation Program (VICP) ............... F-8
The VICP Vaccine Injury Table. .................................. F-9
Qualifications and Aids to Interpretation of Vaccine Injury Table. ................................................. F-10
The Vaccine Adverse Event Reporting System (VAERS)

VAERS is a national vaccine safety surveillance program co-sponsored by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). VAERS collects and analyzes information from reports of adverse events following immunization. Since 1990, VAERS has received over 123,000 reports, most of which describe mild side effects such as fever. Very rarely, people experience serious adverse events following immunization. By monitoring such events, VAERS can help to identify important new safety concerns.

Reporting to VAERS

Who can file a VAERS report: Anyone can submit a VAERS report. Most reports are sent in by vaccine manufacturers (42%) and health care providers (30%). The rest are submitted by state immunization programs (12%), vaccine recipients or their parent/guardians (7%), and other sources (9%).

What adverse events should be reported: VAERS encourages the reporting of any clinically significant adverse event that occurs after the administration of any vaccine licensed in the United States. Report such events even if you are unsure whether a vaccine caused them.

The National Childhood Vaccine Injury Act (NCVIA) requires health care providers to report:
- Any event listed by the vaccine manufacturer as a contraindication to subsequent doses of the vaccine.
- Any event listed in the Reportable Events Table that occurs within the specified time period after vaccination.

A copy of the Reportable Events Table can be found on the next page (F2), or obtained by calling VAERS at 1-800-822-7967 or by downloading it from http://vaers.hhs.gov/pubs.htm.

Filing a VAERS report: Use a VAERS report form (see page F6) to report any adverse event. You can get pre-addressed postage paid report forms by calling VAERS at 1-800-822-7967, or download a printable copy of the VAERS form from the following Internet sites:
- The VAERS Web site at http://vaers.hhs.gov/
- The Centers for Disease Control and Prevention Web site at http://www.cdc.gov/nip/

Instructions are included with the form. You may use a photocopy of the VAERS form to submit a report.

For more information:
- Send e-mail inquiries to info@vaers.org
- Visit the VAERS Web site at: http://vaers.hhs.gov
- Call the toll-free VAERS information line at (800) 822-7967
- Fax inquiries to the toll-free information fax line at (877) 721-0366

This information has been adapted from the VAERS website (http://vaers.hhs.gov).
### Table of Reportable Events Following Vaccination (RET)

<table>
<thead>
<tr>
<th>Vaccine/Toxoid</th>
<th>Event</th>
<th>Interval from Vaccination</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tetanus</strong> in any combination; DTaP, DTP, DTP-Hib, DT, Td, or TT)</td>
<td>A. Anaphylaxis or anaphylactic shock</td>
<td>7 days</td>
</tr>
<tr>
<td></td>
<td>B. Brachial neuritis</td>
<td>28 days</td>
</tr>
<tr>
<td></td>
<td>C. Any sequelae (including death) of above events</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine</td>
<td>See package insert</td>
</tr>
<tr>
<td><strong>Pertussis</strong> in any combination; DTaP, DTP, DTP-HiB, P</td>
<td>A. Anaphylaxis or anaphylactic shock</td>
<td>7 days</td>
</tr>
<tr>
<td></td>
<td>B. Encephalopathy (or encephalitis)</td>
<td>7 days</td>
</tr>
<tr>
<td></td>
<td>C. Any sequelae (including death) of above events</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine</td>
<td>See package insert</td>
</tr>
<tr>
<td><strong>Measles, mumps and rubella</strong> in any combination; MMR, MR, M, or R</td>
<td>A. Anaphylaxis or anaphylactic shock</td>
<td>7 days</td>
</tr>
<tr>
<td></td>
<td>B. Encephalopathy (or encephalitis)</td>
<td>15 days</td>
</tr>
<tr>
<td></td>
<td>C. Any sequelae (including death) of above events</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine</td>
<td>See package insert</td>
</tr>
<tr>
<td><strong>Rubella</strong> in any combination; MMR, MR, R</td>
<td>A. Chronic arthritis</td>
<td>42 days</td>
</tr>
<tr>
<td></td>
<td>B. Any sequelae (including death) of above event</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine</td>
<td>See package insert</td>
</tr>
<tr>
<td><strong>Measles</strong> in any combination; MMR, MR, M</td>
<td>A. Thrombocytopenic purpura</td>
<td>7-30 days</td>
</tr>
<tr>
<td></td>
<td>B. Vaccine-strain measles viral infection in an immunodeficient recipient</td>
<td>6 months</td>
</tr>
<tr>
<td></td>
<td>C. Any sequelae (including death) of above event</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine</td>
<td>See package insert</td>
</tr>
</tbody>
</table>
## Appendix F

<table>
<thead>
<tr>
<th>Oral Polio (OPV)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Paralytic polio</td>
<td>30 days/ 6 months</td>
</tr>
<tr>
<td>B. Vaccine-strain polio viral infection</td>
<td>30 days/ 6 months</td>
</tr>
<tr>
<td>C. Any sequela (including death) of above events</td>
<td>Not applicable</td>
</tr>
<tr>
<td>D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine</td>
<td>See package insert</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inactivated Polio (IPV)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Anaphylaxis or anaphylactic shock</td>
<td>7 days</td>
</tr>
<tr>
<td>B. Any sequelae (including death) of the above event</td>
<td>Not applicable</td>
</tr>
<tr>
<td>C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine</td>
<td>See package insert</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hepatitis B</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Anaphylaxis or anaphylactic shock</td>
<td>7 days</td>
</tr>
<tr>
<td>B. Any sequelae (including death) of the above event</td>
<td>Not applicable</td>
</tr>
<tr>
<td>C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine</td>
<td>See package insert</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Haemophilus influenzae, type b, (conjugate)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Events described in manufacturer's package insert as contraindications to additional doses of vaccine</td>
<td>See package insert</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Varicella</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Intussusception</td>
<td>30 days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rotavirus</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Any sequelae (including death) of the above event</td>
<td>Not applicable</td>
</tr>
<tr>
<td>C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine</td>
<td>See package insert</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pneumococcal conjugate</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Events described in manufacturer's package insert as contraindications to additional doses of vaccine</td>
<td>See package insert</td>
</tr>
</tbody>
</table>

*Effective date: August 26, 2002.*

The Reportable Events Table (RET) reflects what is reportable by law (42 USC 300aa-25) to the Vaccine Adverse Event Reporting System (VAERS) including conditions found in the manufacturers package insert. In addition, individuals are encouraged to report any clinically significant or unexpected events (even if you are not certain the vaccine caused the event) for any vaccine, whether or not it is listed on the RET. Manufacturers are also required by regulation (21CFR 800.80) to report to the VAERS program all adverse events made known to them for any vaccine.
Appendix F

Reportable Events Table Definitions

Anaphylaxis and anaphylactic shock. Anaphylaxis and anaphylactic shock mean an acute, severe, and potentially lethal systemic allergic reaction. Most cases resolve without sequelae. Signs and symptoms begin minutes to a few hours after exposure. Death, if it occurs, usually results from airway obstruction caused by laryngeal edema or bronchospasm and may be associated with cardiovascular collapse.

Brachial neuritis is defined as dysfunction limited to the upper extremity nerve plexus (i.e., its trunks, division, or cords) without involvement of other peripheral (e.g., nerve roots or a single peripheral nerve) or central (e.g., spinal cord) nervous system structures. A deep, steady, often severe aching pain in the shoulder and upper arm usually heralds onset of the condition. The pain is followed in days or weeks by weakness and atrophy in upper extremity muscle groups. Sensory loss may accompany the motor deficits, but is generally a less notable clinical feature.

Encephalopathy. For purposes of the Reportable Events Table, a vaccine recipient shall be considered to have suffered an encephalopathy only if such recipient manifests, within the applicable period, an injury meeting the description below of an acute encephalopathy, and then a chronic encephalopathy persists in such person for more than 6 months beyond the date of vaccination.

1. An acute encephalopathy is one that is sufficiently severe so as to require hospitalization (whether or not hospitalization occurred).
   a. For children less than 18 months of age who present without an associated seizure event, an acute encephalopathy is indicated by a "significantly decreased level of consciousness" (see "D" below) lasting for at least 24 hours. Those children less than 18 months of age who present following a seizure shall be viewed as having an acute encephalopathy if their significantly decreased level of consciousness persists beyond 24 hours and cannot be attributed to a postictal state (seizure) or medication.
   b. For adults and children 18 months of age or older, an acute encephalopathy is one that persists for at least 24 hours and is characterized by at least two of the following:
      i. A significant change in mental status that is not medication related: specifically a confusional state, or a delirium, or a psychosis;
      ii. A significantly decreased level of consciousness, which is independent of a seizure and cannot be attributed to the effects of medication; and
      iii. A seizure associated with loss of consciousness.
   c. Increased intracranial pressure may be a clinical feature of acute encephalopathy in any age group.

2. A "significantly decreased level of consciousness" is indicated by the presence of at least one of the following clinical signs for at least 24 hours or greater:
   a. Decreased or absent response to environment (responds, if at all, only to loud voice or painful stimuli);
   b. Decreased or absent eye contact (does not fix gaze upon family members or other individuals); or
   c. Inconsistent or absent responses to external stimuli (does not recognize familiar people or things).

The following clinical features alone, or in combination, do not demonstrate an acute encephalopathy or a significant change in either mental status or level of consciousness as described above: Sleepiness, irritability (fussiness), high-pitched and unusual screaming, persistent inconsolable crying, and bulging fontanelle. Seizures in themselves are not sufficient to constitute a diagnosis of encephalopathy. In the absence of other evidence of an acute encephalopathy, seizures shall not be viewed as the first symptom or manifestation of the onset of an acute encephalopathy.
3. **Chronic Encephalopathy** occurs when a change in mental or neurologic status, first manifested during the applicable time period, persists for a period of at least 6 months from the date of vaccination. Individuals who return to a normal neurologic state after the acute encephalopathy shall not be presumed to have suffered residual neurologic damage from that event; any subsequent chronic encephalopathy shall not be presumed to be a sequela of the acute encephalopathy. If a preponderance of the evidence indicates that a child's chronic encephalopathy is secondary to genetic, prenatal or perinatal factors, that chronic encephalopathy shall not be considered to be a condition set forth in the Table.

An encephalopathy shall not be considered to be a condition set forth in the Table if it is shown that the encephalopathy was caused by an infection, a toxin, a metabolic disturbance, a structural lesion, a genetic disorder or trauma (without regard to whether the cause of the infection, toxin, trauma, metabolic disturbance, structural lesion or genetic disorder is known).

**Chronic Arthritis.** For purposes of the Reportable Events Table, chronic arthritis may be found in a person with no history in the 3 years prior to vaccination of arthropathy (joint disease) on the basis of:

1. Medical documentation, recorded within 30 days after the onset, of objective signs of acute arthritis (joint swelling) that occurred between 7 and 42 days after a rubella vaccination; and
2. Medical documentation (recorded within 3 years after the onset of acute arthritis) of the persistence of objective signs of intermittent or continuous arthritis for more than 6 months following vaccination.
3. Medical documentation of an antibody response to the rubella virus.

The following shall not be considered as chronic arthritis: Musculoskeletal disorders such as diffuse connective tissue diseases (including but not limited to rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disease, polymyositis/dermatomyositis, fibromyalgia, necrotizing vasculitis and vasculopathies and Sjogren's Syndrome), degenerative joint disease, infectious agents other than rubella (whether by direct invasion or as an immune reaction), metabolic and endocrine diseases, trauma, neoplasms, neuropathic disorders, bone and cartilage disorders and arthritis associated with ankylosing spondylitis, psoriasis, inflammatory bowel disease, Reiter's syndrome, or blood disorders.

**Arthralgia** (joint pain) or stiffness without joint swelling shall not be viewed as chronic arthritis.

**Early-onset Hib disease** is defined as invasive bacterial illness associated with the presence of *Haemophilus influenzae* b (Hib) organism on culture of normally sterile body fluids or tissue, or clinical findings consistent with the diagnosis of epiglottitis. Hib pneumonia qualifies as invasive Hib disease when radiographic findings consistent with the diagnosis of pneumonia are accompanied by a blood culture positive for the Hib organism. Otitis media, in the absence of the above findings, does not qualify as invasive bacterial disease. A child is considered to have suffered an adverse event only if the vaccine was the first Hib immunization received by the child.

**Sequela.** The term "sequela" means a condition or event, which was actually caused by a condition listed in the Reportable Events Table.
## VACCINE ADVERSE EVENT REPORTING SYSTEM

**Appendix F**

**VAERS Number**

**Date Received**

**Patient Identity Kept Confidential**

### Patient Information

- **Last**
- **First**
- **M.I.**
- **Address**
- **City**
- **State**
- **Zip**
- **Telephone no.**

### Vaccine Information

- **Vaccine administered by (Name):**
- **Physician:**
- **Facility Name/Address**
- **Relation**
  - **Vaccine Provider**
  - **Patient/Parent**
  - **Other**
- **Address (if different from patient or provider)**

### Adverse Event Information

- **Date of birth**
- **Patient age**
- **Sex**
  - **M**
  - **F**
- **Date form completed**
  - **mm**
  - **dd**
  - **yy**

### Description of Adverse Event(s)

- **Describe adverse event(s) (symptoms, signs, time course) and treatment, if any**

### Patient Recovery

- **Patient recovered**
  - **YES**
  - **NO**
  - **UNKNOWN**

### Relevant Data

- **Relevant diagnostic tests/laboratory data**

### Vaccines Given

<table>
<thead>
<tr>
<th>Vaccine (type)</th>
<th>Manufacturer</th>
<th>Lot number</th>
<th>Route/Site</th>
<th>No. Previous Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Other Vaccinations

- **Any other vaccinations within 4 weeks prior to the date listed in no. 10**

### Vaccination Sites

- **Vaccinated at:**
  - **Private doctor's office/hospital**
  - **Military clinic/hospital**
  - **Public health clinic/hospital**
  - **Other/unknown**

### Vaccine Purchased

- **Vaccine purchased with:**
  - **Private funds**
  - **Military funds**
  - **Public funds**
  - **Other/unknown**

### Other Medications

### Pre-existing Conditions

### Event Reporting

- **Have you reported this adverse event previously?**
  - **No**
  - **To health department**
  - **To doctor**
  - **To manufacturer**

### Adverse Event Following Prior Vaccination

### Birth Information

- **Weight**
  - **lb.**
  - **oz.**

### Number of Brothers and Sisters

### Event Reporting

- **Only for reports submitted by manufacturer/immunization project**

### Date Received

- **mm**
- **dd**
- **yy**

### Event Reporting

- **Health care providers and manufacturers are required by law (42 USC 300a-23) to report reactions to vaccines listed in the Table of Reportable Events Following Immunization. Reports for reactions to other vaccines are voluntary except when required as a condition of immunization grant awards.**

---

**Form VAERS-1(c)(a)**
"Fold in thirds, tape & mail — DO NOT STAPLE FORM"

BUSINESS REPLY MAIL
FIRST-CLASS MAIL    PERMIT NO. 1895    ROCKVILLE, MD

POSTAGE WILL BE PAID BY ADDRESSEE

VAERS
P.O. Box 1100
Rockville MD 20849-1100

DIRECTIONS FOR COMPLETING FORM
(Additional pages may be attached if more space is needed.)

GENERAL
- Use a separate form for each patient. Complete the form to the best of your abilities. Items 3, 4, 7, 8, 10, 11, and 13 are considered essential and should be completed whenever possible. Parents/Guardians may need to consult the facility where the vaccine was administered for some of the information (such as manufacturer, lot number or laboratory data.)
- Refer to the Reportable Events Table (RET) for events mandated for reporting by law. Reporting for other serious events felt to be related but not on the RET is encouraged.
- Health care providers other than the vaccine administrator (VA) treating a patient for a suspected adverse event should notify the VA and provide the information about the adverse event to allow the VA to complete the form to meet the VA's legal responsibility.
- These data will be used to increase understanding of adverse events following vaccination and will become part of CDC Privacy Act System 09-20-0136, "Epidemiologic Studies and Surveillance of Disease Problems". Information identifying the person who received the vaccine or that person's legal representative will not be made available to the public, but may be available to the vaccinee or legal representative.
- Postage will be paid by addressee. Forms may be photocopied (must be front & back on same sheet).

SPECIFIC INSTRUCTIONS
Form Completed By: To be used by parents/guardians, vaccine manufacturers/distributors, vaccine administrators, and/or the person completing the form on behalf of the patient or the health professional who administered the vaccine.
Item 7: Describe the suspected adverse event. Such things as temperature, local and general signs and symptoms, time course, duration of symptoms, diagnosis, treatment and recovery should be noted.
Item 9: Check "YES" if the patient's health condition is the same as it was prior to the vaccine, "NO" if the patient has not returned to the pre-vaccination state of health, or "UNKNOWN" if the patient's condition is not known.
Item 10: Give dates and times as specifically as you can remember. If you do not know the exact time, please and 11: indicate "AM" or "PM" when possible if this information is known. If more than one adverse event, give the onset date and time for the most serious event.
Item 12: Include "negative" or "normal" results of any relevant tests performed as well as abnormal findings.
Item 13: List ONLY those vaccines given on the day listed in Item 10.
Item 14: List any other vaccines that the patient received within 4 weeks prior to the date listed in Item 10.
Item 16: This section refers to how the person who gave the vaccine purchased it, not to the patient's insurance.
Item 17: List any prescription or non-prescription medications the patient was taking when the vaccine(s) was given.
Item 18: List any short term illnesses the patient had on the date the vaccine(s) was given (i.e., cold, flu, ear infection).
Item 19: List any pre-existing physician-diagnosed allergies, birth defects, medical conditions (including developmental and/or neurologic disorders) for the patient.
Item 21: List any suspected adverse events the patient, or the patient's brothers or sisters, may have had to previous vaccinations. If more than one brother or sister, or if the patient has reacted to more than one prior vaccine, use additional pages to explain completely. For the onset age of a patient, provide the age in months if less than two years old.
Item 26: This space is for manufacturers' use only.
Vaccine Injury Compensation Program (VICP)

The VICP is a no-fault alternative to the traditional tort system for resolving vaccine injury claims. It was established as part of the National Childhood Vaccine Injury Act of 1986, after a rash of lawsuits against vaccine manufacturers and healthcare providers threatened to cause vaccine shortages and reduce vaccination rates.

The VICP covers all vaccines recommended by the Centers for Disease Control and Prevention for routine administration to children. It is administered jointly by the U.S. Department of Health and Human Services (HHS), the U.S. Court of Federal Claims (the Court), and the U.S. Department of Justice (DOJ). The VICP is located in the HRSA Healthcare Systems Bureau. Covered vaccines and compensable injuries are described on the “Vaccine Injury Table” (see following page - F9).

The Claims Process

An individual claiming a vaccine-related injury or death files a petition for compensation with the Court, and is may be represented by an attorney. The Secretary of HHS is named as the Respondent.

An HHS physician reviews the petition to determine whether it meets the medical criteria for compensation. This recommendation is provided to the Court through a Respondent's report filed by the DOJ. The HHS position is presented by an attorney from the DOJ in hearings before a "special master," who makes the decision for compensation under the VICP. A decision may be appealed to the Court, then to the Federal Circuit Court of Appeals, and eventually to the U.S. Supreme Court.

If a case is found eligible for compensation, the amount of the award is usually negotiated between the DOJ and the petitioner's attorneys. If the attorneys can't agree, the case is scheduled for a hearing for the special master to assess the amount of compensation. Compensable claims, and even most claims found to be non-compensable, are awarded reimbursement for attorney's fees and costs. A petitioner may file a claim in civil court against the vaccine company and/or the vaccine administrator only after first filing a claim under the VICP and then rejecting the decision of the Court.

For more information, including information about restrictions that apply to filing a petition, visit the VICP website at http://www.hrsa.gov/osp/vicp or phone 1-800-338-2382.

For information on the Rules of the Court, including requirements for filing a petition, visit the Court's Website at http://www.uscfc.uscourts.gov/osmPage.htm or phone (202)357-6400.

This information has been adapted from the VICP website (http://www.hrsa.gov/osp/vicp)
# National Childhood Vaccine Injury Act

Vaccine Injury Table

<table>
<thead>
<tr>
<th>Appendix F</th>
<th>Vaccine</th>
<th>Adverse Event</th>
<th>Ti</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Tetanus toxoid-containing vaccines (e.g., DTaP, Tdap, DTP-Hib, DT, Td, TT)</td>
<td>A Anaphylaxis or anaphylactic shock</td>
<td>0-4 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B Brachial neuritis</td>
<td>2-28</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C Any acute complication or sequela (including death) of above events</td>
<td>Not a</td>
</tr>
<tr>
<td>II</td>
<td>Pertussis antigen-containing vaccines (e.g., DTaP, Tdap, DTP, P, DTP-Hib)</td>
<td>A Anaphylaxis or anaphylactic shock</td>
<td>0-4 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B Encephalopathy (or encephalitis)</td>
<td>0-72</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C Any acute complication or sequela (including death) of above events</td>
<td>Not a</td>
</tr>
<tr>
<td>III</td>
<td>Measles, mumps and rubella virus-containing vaccines in any combination (e.g., MMR, MR, M, R)</td>
<td>A Anaphylaxis or anaphylactic shock</td>
<td>0-4 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B Encephalopathy (or encephalitis)</td>
<td>5-15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C Any acute complication or sequela (including death) of above events</td>
<td>Not a</td>
</tr>
<tr>
<td>IV</td>
<td>Rubella virus-containing vaccines (e.g., MMR, MR, R)</td>
<td>A Chronic arthritis</td>
<td>7-42</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B Any acute complication or sequela (including death) of above event</td>
<td>Not a</td>
</tr>
<tr>
<td>V</td>
<td>Measles virus-containing vaccines (e.g., MMR, MR, M)</td>
<td>A Thrombocytopenic purpura</td>
<td>7-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B Vaccine-Strain Measles Viral Infection in an immunodeficient recipient</td>
<td>0-6 n</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C Any acute complication or sequela (including death) of above events</td>
<td>Not a</td>
</tr>
<tr>
<td>VI</td>
<td>Polio live virus-containing vaccines (OPV)</td>
<td>A Paralytic polio</td>
<td>0-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- in a non-immunodeficient recipient</td>
<td>0-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- in an immunodeficient recipient</td>
<td>0-6 n</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- in a vaccine assoc. community case</td>
<td>Not a</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B Vaccine-strain polio viral infection</td>
<td>0-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- in a non-immunodeficient recipient</td>
<td>0-6 n</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- in an immunodeficient recipient</td>
<td>Not a</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- in a vaccine assoc. community case</td>
<td>Not a</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C Any acute complication or sequela (including death) of above events</td>
<td>Not a</td>
</tr>
<tr>
<td>VII</td>
<td>Polio inactivated-virus containing vaccines (e.g., IPV)</td>
<td>A Anaphylaxis or anaphylactic shock</td>
<td>0-4 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B Any acute complication or sequela (including death) of above event</td>
<td>Not a</td>
</tr>
<tr>
<td>VIII</td>
<td>Hepatitis B antigen-containing vaccines</td>
<td>A Anaphylaxis or anaphylactic shock</td>
<td>0-4 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B Any acute complication or sequela (including death) of above event</td>
<td>Not a</td>
</tr>
<tr>
<td>IX</td>
<td>Haemophilus influenzae type b polysaccharide conjugate vaccines</td>
<td>A No condition specified for compensation</td>
<td>Not a</td>
</tr>
<tr>
<td>X</td>
<td>Varicella vaccine</td>
<td>A No condition specified for compensation</td>
<td>Not a</td>
</tr>
<tr>
<td>XI</td>
<td>Rotavirus vaccine</td>
<td>A No condition specified for compensation</td>
<td>Not a</td>
</tr>
<tr>
<td>XII</td>
<td>Vaccines containing live, oral, rhesus-based rotavirus</td>
<td>A Intussusception</td>
<td>0-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B Any acute complication or sequela (including death) of above event</td>
<td>Not a</td>
</tr>
<tr>
<td>XIII</td>
<td>Pneumococcal conjugate vaccines</td>
<td>A No condition specified for compensation</td>
<td>Not a</td>
</tr>
</tbody>
</table>
Qualifications and Aids to Interpretation

(1) **Anaphylaxis and anaphylactic shock** mean an acute, severe, and potentially lethal systemic allergic reaction. Most cases resolve without sequelae. Signs and symptoms begin minutes to a few hours after exposure. Death, if it occurs, usually results from airway obstruction caused by laryngeal edema or bronchospasm and may be associated with cardiovascular collapse. Other significant clinical signs and symptoms may include the following: Cyanosis, hypotension, bradycardia, tachycardia, arrhythmia, edema of the pharynx and/or trachea and/or larynx with stridor and dyspnea. Autopsy findings may include acute emphysema which results from lower respiratory tract obstruction, edema of the hypopharynx, epiglottis, larynx, or trachea and minimal findings of eosinophilia in the liver, spleen and lungs. When death occurs within minutes of exposure and with out signs of respiratory distress, there may not be significant pathologic findings.

(2) **Encephalopathy**. For purposes of the Vaccine Injury Table, a vaccine recipient shall be considered to have suffered an encephalopathy only if such recipient manifests, within the applicable period, an injury meeting the description below of an acute encephalopathy, and then a chronic encephalopathy persists in such person for more than 6 months beyond the date of vaccination.

   (i) An acute encephalopathy is one that is sufficiently severe so as to require hospitalization (whether or not hospitalization occurred).

      (A) For children less than 18 months of age who present without an associated seizure event, an acute encephalopathy is indicated by a "significantly decreased level of consciousness" (see "D" below) lasting for at least 24 hours. Those children less than 18 months of age who present following a seizure shall be viewed as having an acute encephalopathy if their significantly decreased level of consciousness persists beyond 24 hours and cannot be attributed to a postictal state (seizure) or medication.

      (B) For adults and children 18 months of age or older, an acute encephalopathy is one that persists for at least 24 hours and characterized by at least two of the following:

         (1) A significant change in mental status that is not medication related; specifically a confusional state, or a delirium, or a psychosis;

         (2) A significantly decreased level of consciousness, which is independent of a seizure and cannot be attributed to the effects of medication; and

         (3) A seizure associated with loss of consciousness.

      (C) Increased intracranial pressure may be a clinical feature of acute encephalopathy in any age group.

      (D) A "significantly decreased level of consciousness" is indicated by the presence of at least one of the following clinical signs for at least 24 hours or greater (see paragraphs (2)(I)(A) and (2)(I)(B) of this section for applicable timeframes):

         (1) Decreased or absent response to environment (responds, if at all, only to loud voice or painful stimuli);

         (2) Decreased or absent eye contact (does not fix gaze upon family members or other individuals); or

         (3) Inconsistent or absent responses to external stimuli (does not recognize familiar people or things).

   (E) The following clinical features alone, or in combination, do not demonstrate an acute encephalopathy or a significant change in either mental status or level of consciousness as described above: Sleepiness, irritability (fussiness), high-pitched and unusual screaming, persistent inconsolable crying, and bulging fontanelle. Seizures in themselves are not sufficient to constitute a diagnosis of encephalopathy. In the absence of other evidence of an acute encephalopathy, seizures shall not be viewed as the first symptom or manifestation of the onset of an acute encephalopathy.

   (ii) Chronic encephalopathy occurs when a change in mental or neurologic status, first manifested during the applicable time period, persists for a period of at least 6 months from the date of vaccination. Individuals who return to a normal neurologic state after the acute encephalopathy shall not be presumed
to have suffered residual neurologic damage from that event; any subsequent chronic encephalopathy shall not be presumed to be a sequela of the acute encephalopathy. If a preponderance of the evidence indicates that a child's chronic encephalopathy is secondary to genetic, prenatal or perinatal factors, that chronic encephalopathy shall not be considered to be a condition set forth in the Table.

(iii) An encephalopathy shall not be considered to be a condition set forth in the Table if in a proceeding on a petition, it is shown by a preponderance of the evidence that the encephalopathy was caused by an infection, a toxin, a metabolic disturbance, a structural lesion, a genetic disorder or trauma (without regard to whether the cause of the infection, toxin, trauma, metabolic disturbance, structural lesion or genetic disorder is known). If at the time a decision is made on a petition filed under section 2111(b) of the Act for a vaccine-related injury or death, it is not possible to determine the cause by a preponderance of the evidence of an encephalopathy, the encephalopathy shall be considered to be a condition set forth in the Table.

(iv) In determining whether or not an encephalopathy is a condition set forth in the Table, the Court shall consider the entire medical record.

3) **Seizure and convulsion.** For purposes of paragraphs (b)(2) of this section, the terms, "seizure" and "convulsion" include myoclonic, generalized tonic-clonic (grand mal), and simple and complex partial seizures. Absence (petit mal) seizures shall not be considered to be a condition set forth in the Table. Jerking movements or staring episodes alone are not necessarily an indication of seizure activity.

4) **Sequela.** The term "sequela" means a condition or event which was actually caused by a condition listed in the Vaccine Injury Table.

5) **Chronic Arthritis.** For purposes of the Vaccine Injury Table, chronic arthritis may be found in a person with no history in the 3 years prior to vaccination of arthropathy (joint disease) on the basis of:

(A) Medical documentation, recorded within 30 days after the onset, of objective signs of acute arthritis (joint swelling) that occurred between 7 and 42 days after a rubella vaccination;

(B) Medical documentation (recorded within 3 years after the onset of acute arthritis) of the persistence of objective signs of intermittent or continuous arthritis for more than 6 months following vaccination;

(C) Medical documentation of an antibody response to the rubella virus.

For purposes of the Vaccine Injury Table, the following shall not be considered as chronic arthritis:

Musculoskeletal disorders such as diffuse connective tissue diseases (including but not limited to rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disease, polymyositis/dermatomyositis, fibromyalgia, necrotizing vasculitis and vasculopathies and Sjogren's Syndrome), degenerative joint disease, infectious agents other than rubella (whether by direct invasion or as an immune reaction), metabolic and endocrine diseases, trauma, neoplasms, neuropathic disorders, bone and cartilage disorders and arthritis associated with ankylosing spondylitis, psoriasis, inflammatory bowel disease, Reiter's syndrome, or blood disorders.

Arthralgia (joint pain) or stiffness without joint swelling shall not be viewed as chronic arthritis for purposes of the Vaccine Injury Table.

6) **Brachial neuritis** is defined as dysfunction limited to the upper extremity nerve plexus (i.e., its trunks, divisions, or cords) without involvement of other peripheral (e.g., nerve roots or a single peripheral nerve) or central (e.g., spinal cord) nervous system structures. A deep, steady, often severe aching pain in the shoulder and upper arm usually heralds onset of the condition. The pain is followed in days or weeks by weakness and atrophy in upper extremity muscle groups. Sensory loss may accompany the motor deficits, but is generally a less notable clinical feature. The neuritis, or plexopathy, may be present on the same side or the opposite side of the injection; it is sometimes bilateral, affecting both upper extremities. Weakness is required before the diagnosis can be made. Motor, sensory, and reflex findings on physical examination and the results of nerve conduction and electromyographic studies must be consistent in confirming that dysfunction is attributable to the brachial plexus. The condition should thereby be distinguishable from conditions that may give rise to dysfunction of nerve roots (i.e., radiculopathies) and peripheral nerves (i.e., including multiple mononeuropathies), as well as other peripheral and central nervous system structures (e.g., cranial neuropathies and myelopathies).
(7) **Thrombocytopenic purpura** is defined by a serum platelet count less than 50,000/mm³. Thrombocytopenic purpura does not include cases of thrombocytopenia associated with other causes such as hypersplenism, autoimmune disorders (including alloantibodies from previous transfusions) myelodysplasias, lymphoproliferative disorders, congenital thrombocytopenia or hemolytic uremic syndrome. This does not include cases of immune (formerly called idiopathic) thrombocytopenic purpura (ITP) that are mediated, for example, by viral or fungal infections, toxins or drugs. Thrombocytopenic purpura does not include cases of thrombocytopenia associated with disseminated intravascular coagulation, as observed with bacterial and viral infections. Viral infections include, for example, those infections secondary to Epstein Barr virus, cytomegalovirus, hepatitis A and B, rhinovirus, human immunodeficiency virus (HIV), adenovirus, and dengue virus. An antecedent viral infection may be demonstrated by clinical signs and symptoms and need not be confirmed by culture or serologic testing. Bone marrow examination, if performed, must reveal a normal or an increased number of megakaryocytes in an otherwise normal marrow.

(8) **Vaccine-strain measles viral infection** is defined as a disease caused by the vaccine-strain that should be determined by vaccine specific monoclonal antibody or polymerase chain reaction tests.

(9) **Vaccine-strain polio viral infection** is defined as a disease caused by poliovirus that is isolated from the affected tissue and should be determined to be the vaccine-strain by oligonucleotide or polymerase chain reaction. Isolation of poliovirus from the stool is not sufficient to establish a tissue specific infection or disease caused by vaccine-strain poliovirus.